Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Lung Neoplasms 12Multiple Myeloma 11Lymphoma 10Neoplasm Metastasis 9Melanoma 7Leukemia, Myeloid, Acute 7Prostatic Neoplasms 6Neuroblastoma 6Carcinoma, Non-Small-Cell Lung 6Wilms Tumor 5Medulloblastoma 5Lymphoma, Non-Hodgkin 5Fallopian Tube Neoplasms 5Burkitt Lymphoma 5Breast Neoplasms 5Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Rhabdoid Tumor 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Osteosarcoma 4Neuroectodermal Tumors, Primitive, Peripheral 4Histiocytosis, Langerhans-Cell 4Hepatoblastoma 4Glioma 4Ependymoma 4Central Nervous System Neoplasms 4Sarcoma, Kaposi 3Sarcoma 3

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Fallopian Tube Mucinous Adenocarcinoma × Specimen Handling × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡